ALLANTOIN ASCORBATE

US Approved OTC

First approved in 1961

Details

Stereochemistry	EPIMERIC
Molecular Formula	C6H8O6.C4H6N4O3
Molecular Weight	334.2396
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)NC1NC(=O)NC1=O.[H][C@@]2(OC(=O)C(O)=C2O)[C@@H](O)CO

InChI

InChIKey=BMZVXYKKNCVBBF-RXSVEWSESA-N

InChI=1S/C6H8O6.C4H6N4O3/c7-1-2(8)5-3(9)4(10)6(11)12-5;5-3(10)6-1-2(9)8-4(11)7-1/h2,5,7-10H,1H2;1H,(H3,5,6,10)(H2,7,8,9,11)/t2-,5+;/m0./s1

HIDE SMILES / InChI

Description
Sources: http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfhttp://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883
Curator's Comment: description was created based on several sources, including: http://tri-k.com/acloxa

Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Chaffing 5 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa716980-803d-4d33-8fce-ee7aa6da0830	Preventing	Not Provided 504	BODYGLIDE FOR HER Approved Use helps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns. Launch Date 2009
Functional dyspepsia 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Preclinical	Unknown Approved Use Unknown
Gastric ulcer 67 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Approved 8429	Unknown Approved Use protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Duodenal ulcer 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Approved 8429	Unknown Approved Use protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.
Gastritis 45 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26620883	Primary	Approved 8429	Unknown Approved Use protects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis.

C_max

Value	Dose	Co-administered	Analyte	Population
6.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/	10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALLANTOIN plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
30 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/	10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALLANTOIN plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/	10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:		ALLANTOIN plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:15676	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15676
ChemicalBook	CB3215461	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3215461
MolPort	MolPort-001-779-876	https://www.molport.com/shop/molecule-link/MolPort-001-779-876
eMolecules	476195	https://www.emolecules.com/cgi-bin/more?vid=476195

PubMed

Title	Date	PubMed

Sample Use Guides

In Vivo Use Guide

Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5% Baby products: creams; powders: 0.2-0.5%

Route of Administration: Topical

In Vitro Use Guide

In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.

Name

Type

Language

ALLANTOIN ASCORBATE

Official Name

English

UREA, (2,5-DIOXO-4-IMIDAZOLIDINYL)-, COMPD. WITH L-ASCORBIC ACID (1:1)

Common Name

English

ALLANTOIN-ASCORBIC ACID COMPOUND

Common Name

English

ALLANTOIN ASCORBATE [INCI]

Common Name

English

L-ASCORBIC ACID, COMPD. WITH N-(2,5-DIOXO-4-IMIDAZOLIDINYL)UREA (1:1)

Common Name

English

Code System Code Type Description

PUBCHEM

67732897